TORONTO, ONTARIO--(Marketwire - Nov. 29, 2011) - Gemoscan Canada, Inc. ("Gemoscan" or the "Corporation") - (CNSX:GES) (MUN:1GE.MU - News) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the "Exchange") to list its Class A Shares. The listing is conditional upon the Corporation completing a minimum $500,000 offering resulting in at least 100 new shareholders each holding a board lot. The listing is also subject to the other standard listing conditions of the Exchange. All conditions must be satisfied by February 16, 2012.
Macquarie Private Wealth Inc. has acted as the Corporation's sponsor in connection with the Corporation's application to list its shares on the Exchange.
A completed listing application has been filed on SEDAR at (www.sedar.com).
The Corporation is also pleased to announce that Ms. Kathleen Skerrett has joined the board of directors. Ms. Skerrett is the Corporation's corporate counsel and is a partner with Gardiner Roberts LLP.practicing in the area of corporate and securities law.
The Corporation is in the process of negotiating the terms of the required financing and hopes to be able to make an announcement shortly.
Founded in 2003 Gemoscan owns and markets the Hemocode System, a well-being assessment and treatment program that uses its own patented technology and services to detect and provide recommendations for the management of food intolerance and its often associated lifestyle affecting conditions such as fibromyalgia, chronic migraines and headaches, weight management, sleeplessness and others.
Gemoscan trades on the Canadian National Stock Exchange under the ticker GES and is quoted on the Munich Stock Exchange under the ticker 1GE.
This news release contains certain "forward-looking information". All statements, other than statements of historical fact, that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Company website: www.hemocode.com
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.